OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi ...

Nantes, France, April 23, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company ...